Alice Gottlieb

Summary

Affiliation: Tufts Medical Center
Country: USA

Publications

  1. pmc Role of golimumab, a TNF-alpha inhibitor, in the treatment of the psoriatic arthritis
    Melissa A Michelon
    Tufts University School of Medicine
    Clin Cosmet Investig Dermatol 3:79-84. 2010
  2. ncbi request reprint Psoriasis outcome measures: a report from the GRAPPA 2012 annual meeting
    Alice B Gottlieb
    Department of Dermatology, Tufts Medical Center, Boston, Massachusetts 02111 1533, USA
    J Rheumatol 40:1428-33. 2013
  3. pmc Phosphodiesterase 4-targeted treatments for autoimmune diseases
    Neal Kumar
    Department of Dermatology, Tufts Medical Center, 800 Washington Street 114, Boston, MA 02111, USA
    BMC Med 11:96. 2013
  4. pmc A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis
    A B Gottlieb
    Tufts Medical Center, Boston, MA, USA
    Br J Dermatol 167:649-57. 2012
  5. doi request reprint Ustekinumab for psoriasis and psoriatic arthritis
    Ari Michael Goldminz
    Department of Dermatology, Tufts Medical Center, Boston, Massachusetts 02111, USA
    J Rheumatol Suppl 89:86-9. 2012
  6. doi request reprint Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis
    A B Gottlieb
    Tufts Medical Center, 800 Washington Street, Boston, MA 02111, USA
    Br J Dermatol 165:652-60. 2011
  7. doi request reprint Validation and response to treatment of a pruritus self-assessment tool in patients with moderate to severe psoriasis
    Alice Gottlieb
    Tufts Medical Center, Boston, Massachusetts 02111 1533, USA
    J Am Acad Dermatol 63:580-6. 2010
  8. doi request reprint Comorbidities in patients with psoriasis
    Alice B Gottlieb
    Tufts Medical Center, Boston, Mass, USA
    Am J Med 122:1150.e1-9. 2009
  9. doi request reprint Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics
    Alice Gottlieb
    Department of Dermatology, Tufts New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts, USA
    J Am Acad Dermatol 58:851-64. 2008
  10. doi request reprint Pilot, multicenter, double-blind, randomized placebo-controlled bilateral comparative study of a combination of calcipotriene and nicotinamide for the treatment of psoriasis
    Danielle Levine
    Department of Dermatology, Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts 02111, USA
    J Am Acad Dermatol 63:775-81. 2010

Detail Information

Publications15

  1. pmc Role of golimumab, a TNF-alpha inhibitor, in the treatment of the psoriatic arthritis
    Melissa A Michelon
    Tufts University School of Medicine
    Clin Cosmet Investig Dermatol 3:79-84. 2010
    ..This new biologic therapy provides physicians with another option in the treatment of this inflammatory arthritis while offering patients certain advantages over other TNF antagonists...
  2. ncbi request reprint Psoriasis outcome measures: a report from the GRAPPA 2012 annual meeting
    Alice B Gottlieb
    Department of Dermatology, Tufts Medical Center, Boston, Massachusetts 02111 1533, USA
    J Rheumatol 40:1428-33. 2013
    ....
  3. pmc Phosphodiesterase 4-targeted treatments for autoimmune diseases
    Neal Kumar
    Department of Dermatology, Tufts Medical Center, 800 Washington Street 114, Boston, MA 02111, USA
    BMC Med 11:96. 2013
    ....
  4. pmc A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis
    A B Gottlieb
    Tufts Medical Center, Boston, MA, USA
    Br J Dermatol 167:649-57. 2012
    ..Etanercept plus methotrexate combination therapy has not been adequately investigated in psoriasis...
  5. doi request reprint Ustekinumab for psoriasis and psoriatic arthritis
    Ari Michael Goldminz
    Department of Dermatology, Tufts Medical Center, Boston, Massachusetts 02111, USA
    J Rheumatol Suppl 89:86-9. 2012
    ..Ustekinumab appears to be well tolerated, but its longterm safety profile is not yet known...
  6. doi request reprint Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis
    A B Gottlieb
    Tufts Medical Center, 800 Washington Street, Boston, MA 02111, USA
    Br J Dermatol 165:652-60. 2011
    ..The anti-interleukin-12/23p40 monoclonal antibody briakinumab has been shown in a phase II study to be effective psoriasis treatment...
  7. doi request reprint Validation and response to treatment of a pruritus self-assessment tool in patients with moderate to severe psoriasis
    Alice Gottlieb
    Tufts Medical Center, Boston, Massachusetts 02111 1533, USA
    J Am Acad Dermatol 63:580-6. 2010
    ..Pruritus is a common symptom of psoriasis. In many clinical trials of psoriasis treatments, severity of pruritus is a patient-reported outcome...
  8. doi request reprint Comorbidities in patients with psoriasis
    Alice B Gottlieb
    Tufts Medical Center, Boston, Mass, USA
    Am J Med 122:1150.e1-9. 2009
    ....
  9. doi request reprint Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics
    Alice Gottlieb
    Department of Dermatology, Tufts New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts, USA
    J Am Acad Dermatol 58:851-64. 2008
    ..We will discuss the use of disease-modifying antirheumatic drugs and the biologic therapies in the treatment of patients with moderate to severe psoriatic arthritis...
  10. doi request reprint Pilot, multicenter, double-blind, randomized placebo-controlled bilateral comparative study of a combination of calcipotriene and nicotinamide for the treatment of psoriasis
    Danielle Levine
    Department of Dermatology, Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts 02111, USA
    J Am Acad Dermatol 63:775-81. 2010
    ..By inhibiting proinflammatory cytokines such as interleukin-12, interleukin-23, and tumor necrosis factor-alfa, nicotinamide may enhance the efficacy of calcipotriene therapy when used in combination...
  11. doi request reprint Evaluation and management of psoriasis: an internist's guide
    Danielle Levine
    Department of Dermatology, Tufts Medical Center, Tufts University School of Medicine, 800 Washington Street, Boston, MA 02111, USA
    Med Clin North Am 93:1291-303. 2009
    ....
  12. doi request reprint A series of critically challenging case scenarios in moderate to severe psoriasis: a Delphi consensus approach
    Bruce Strober
    Department of Dermatology, New York University Medical Center, New York, NY, USA
    J Am Acad Dermatol 61:S1-S46. 2009
    ..The final rankings and analysis provide guidance for practical, safe, and efficacious treatment options in a number of complex psoriasis scenarios...
  13. ncbi request reprint Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial
    Alice Gottlieb
    Tufts Medical Center, Boston, MA, USA
    Lancet 373:633-40. 2009
    ..Ustekinumab is a human monoclonal antibody that inhibits receptor-binding of these cytokines. We aimed to assess the efficacy and safety of ustekinumab for psoriatic arthritis in this phase II study...
  14. ncbi request reprint Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial
    Stephen Tyring
    Department of Dermatology, University of Texas Health Science Center at Houston, Houston, TX, USA
    Lancet 367:29-35. 2006
    ..Psoriasis has substantial psychological and emotional effects. We assessed the effect of etanercept, an effective treatment for the clinical symptoms of psoriasis, on fatigue and symptoms of depression associated with the condition...
  15. ncbi request reprint Cutaneous lupus erythematosus and anti-TNF-alpha therapy: a case report with review of the literature
    Danielle Levine
    Department of Dermatology, Tufts Medical Center, Tufts University School of Medicine, Boston, MA 02111, USA
    J Drugs Dermatol 9:1283-7. 2010
    ..The authors then propose possible approaches to the management of anti-TNF-alpha therapy-induced cutaneous LE...